Patient-centered Communication About Healthy Weight in Early Breast Cancer

Clinic-based "Patient-Centered Communication About Healthy Weight" (PCC-HW) in a Diverse Sample of Women With Early Breast Cancer

Comorbidities in breast cancer survival account for 49% of overall survival difference between black and white women. Many obesity-related comorbidities disproportionately affect black women, therefore pointing to a need to address obesity related comorbidities in survival disparities in early breast cancer patients. This study tinvestigates how messages and messaging about healthy weight can be tailored for racially diverse breast cancer survivors with obesity in order to ensure that clinic-based communications between patients and their oncology provider are patient-centered and culturally sensitive.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Other: Focus Group

Detailed Description

The overall goal of this research is to collect essential input for the future development of a quality improvement intervention to foster "Patient-Center Communication about Healthy Weigh in clinical practice

Primary Objective:

1. Understand patient-centered perspectives on health weight communication with oncology clinicians by conducting focus groups

   Secondary Objective

2. Understand oncology clinician perspectives on patient center communications for healthy weight interactions through semi-structured interviews.

• Study Type: Observational
• Enrollment (Actual): 39

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina at Chapel Hill

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 99 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Breast Cancer patients and Breast oncology providers will be eligible for this study

Description

Inclusion Criteria for Breast Cancer Cohort:

• Age 21 or older
• Diagnosed with early breast cancer, Stages I-III
• Completed primary treatment (Surgery, chemotherapy, radiation) within past 2 years
• Body mass Index of equal or greater than 30

Exclusion Criteria:

• Cannot understand and speak English

INclusion Criteria for Oncology provider cohort:

• Breast cancer oncology provider in North Carolina with MD/DO/PA/NP/RN
• associated with community-based practices

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Early Breast Cancer Patients; Early breast cancer patients (Stage I-III) who have completed primary treatment with a current Body mass index (BMI) over 30.	Other: Focus Group; Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
Medical Oncology Clinicians; Oncology providers associated with community-based practices	Other: Focus Group; Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feedback from patients regarding healthy weight communication through focus groups	Summary of conversation based on 5A's Behavioral Change Model	3 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feedback from oncology providers regarding healthy weight communication through semi-structured interview	Provider suggestions on how to implement 5A's Behavioral change model into patient care	3 year

Collaborators and Investigators

• Sponsor: UNC Lineberger Comprehensive Cancer Center
• Collaborators: Pfizer; American Cancer Society, Inc.
• Investigators: Principal Investigator: Kirsten Nyrop, PhD, University of North Carolina, Chapel Hill

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 15, 2020
• Primary Completion (ACTUAL): September 29, 2020
• Study Completion (ACTUAL): September 29, 2020

Study Registration Dates

• First Submitted: August 4, 2020
• First Submitted That Met QC Criteria: August 4, 2020
• First Posted (ACTUAL): August 7, 2020

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2022
• Last Update Submitted That Met QC Criteria: July 26, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: LCCC 1954

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No